INTRALESIONAL ALFA-2A INTERFERON THERAPY FOR BASAL-CELL CARCINOMA

Basal cell carcinoma (BCC) is an epithelial tumour of the skin that ar ises from basal cells of the epidermis and its appendages. There are s ome therapeutic models for BCC, and one of these is intralesional inte rferon. Thirteen patients with histopathologically-proven BCC on their faces or trunk were treated with intralesional interferon alfa-2a. On ly 2 of 13 patients required surgery:due to insufficient improvement. All the others were completely cured in 12 to 36 weeks. We concluded t hat intralesional interferon therapy of sufficient dose and duration f or noduloulcerative and superficial BCC is an encouraging alternative to surgery and other treatment models.